The firm’s M&A team assisted Aspironix, a Czech company active also in Slovakia, Poland and other countries, in its sale to Asker Healthcare Group of Sweden. 

Founded in the Czech Republic in 2011, Aspironix specialises in medical technology, specifically on providing cutting-edge medical devices and services, particularly in the areas of cardiology, surgery, wounding care, AI diagnostics, and critical care. 

Mainly Martin Peckl, partner of the firm, Pavel Ondrák, counsel, and Johana Němečková participated in the transaction. 

The integration into the Asker Healthcare Group will enable Aspironix to focus on further company growth and innovation, among other things. 

The transaction was completed in all jurisdictions in August 2024.